Coinbase seeks CFTC approval for U.S. single-stock perpetuals
Coinbase filed with the CFTC to list single-stock perpetual futures in the U.S., seeking approval for 24/5 contracts that let traders gain exposure to stocks without owning them.
Coinbase Derivatives filed with the Commodity Futures Trading Commission on Friday seeking approval to list single-stock perpetual futures for U.S. customers. The proposal would allow perpetual contracts tied to individual U.S. equities to trade 24 hours a day, five days a week.
The filing asks the CFTC to classify the products as single-stock futures. Coinbase’s paperwork lists an initial roster of roughly 50 to 60 names, including Apple, Microsoft, Tesla and Nvidia.
Perpetual futures do not have a fixed expiration date and typically use a funding mechanism to keep contract prices aligned with the underlying cash market. The contracts would let traders take leveraged positions in a single equity without owning the shares and hold those positions while margin requirements are met.
The application follows a regulatory step on Sept. 1, when Coinbase Derivatives filed a Form 1-N with the Securities and Exchange Commission to register as a national securities exchange for the purpose of offering security futures. Coinbase launched stock perpetuals for eligible customers outside the U.S. in March; those products were not available to U.S. persons at launch.
Coinbase is seeking CFTC authorization for the listing, the trading rules and the surveillance protocols required for single-stock futures. The filing is now under CFTC review; approval will determine whether and under what conditions the contracts can be offered to U.S. customers.
The material on GNcrypto is intended solely for informational use and must not be regarded as financial advice. We make every effort to keep the content accurate and current, but we cannot warrant its precision, completeness, or reliability. GNcrypto does not take responsibility for any mistakes, omissions, or financial losses resulting from reliance on this information. Any actions you take based on this content are done at your own risk. Always conduct independent research and seek guidance from a qualified specialist. For further details, please review our Terms, Privacy Policy and Disclaimers.






